BackBiodexa Pharmaceuticals Plc Overview

Biodexa Pharmaceuticals Plc Total Current Liabilities

Biodexa Pharmaceuticals Plc's total current liabilities is $6.1M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$6.12M
21.54% YoYΔ $1.08M vs prior year quarter

Peer average

Loading

Biodexa Pharmaceuticals Plc Total Current Liabilities History

Loading

Biodexa Pharmaceuticals Plc vs. peers: Total Current Liabilities Comparison

Loading

Biodexa Pharmaceuticals Plc Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Biodexa Pharmaceuticals Plc (BDRX) FAQ

As of the most recent data (December 2025), BDRX shows a total current liabilities of $6.1M. That compares with $5M in the prior-year period — up 21.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BDRX's total current liabilities is now $6.1M (was $5M) — a 21.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Biodexa Pharmaceuticals Plc is outperforming or lagging.

Tracking BDRX's total current liabilities over time shows whether Biodexa Pharmaceuticals Plc is scaling, shrinking, or reshaping that part of the business. The current reading is $6.1M That compares with $5M in the prior-year period — up 21.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Biodexa Pharmaceuticals Plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $6.1M) with ownership activity and broader fundamentals.

Biodexa Pharmaceuticals Plc's total current liabilities is $6.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.